Results 11 to 20 of about 268,746 (338)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors

Zhongliu Fangzhi Yanjiu, 2021
Cardiotoxicity is a serious complication of antineoplastic drugs. With the continuous development of antineoplastic drugs, immune checkpoint inhibitors have been used in the treatment of a variety of cancers.
YU Lin, LI Guangping, ZHOU Changyu, FU Huaying   +3 more
doaj   +1 more source

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity. [PDF]

, 2020
Although immunotherapies have achieved remarkable salutary effects among subgroups of advanced cancers, most patients do not respond. We comprehensively evaluated biomarkers associated with the "cancer-immunity cycle" in the pan-cancer setting in order ...
Dressman, Devin, Eskander, Ramez, Glenn, Sean T, Goodman, Aaron, Ikeda, Sadakatsu, Kato, Shumei, Kumaki, Yuichi, Kurzrock, Razelle, Lee, Suzanna, Lenzo, Felicia L, Morrison, Carl, Nikanjam, Mina, Okamura, Ryosuke, Papanicolau-Sengos, Antonios   +13 more
core   +1 more source

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

Journal for ImmunoTherapy of Cancer, 2019
Background In non-small cell lung cancer, response rates to chemotherapy given after immune checkpoint inhibitors has been reported to be higher compared to response rates to chemotherapy given before immune checkpoint inhibitors.
Rayan Alsuwaigh, Joycelyn Lee, Gloria Chan, Cheng Ean Chee, Su Pin Choo   +4 more
doaj   +1 more source

Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition

JEADV Clinical Practice, 2023
The introduction of immune checkpoint inhibitors and targeted therapies has revolutionized melanoma treatment. The downside are immune‐mediated adverse events which are frequent and require close patient management.
Kristine E. Mayer, Thomas Gan, Jochen Gaa, Tilo Biedermann, Christian Posch   +4 more
doaj   +1 more source

Immune checkpoint inhibitors in renal cell carcinoma [PDF]

, 2017
The immune system has long been known to play a critical role in the body's defence against cancer, and there have been multiple attempts to harness it for therapeutic gain.
Jones, Robert J., Ross, Kirsty
core   +1 more source

Challenges of Immune Checkpoint Inhibitors in Treatment of Non-small Cell Lung Cancer

Zhongliu Fangzhi Yanjiu, 2019
With the gradually in-depth research of immune checkpoint, the checkpoint inhibitors, such as programmed death-1(PD-1) inhibitors, programmed death–ligand 1(PD-L1) inhibitors and cytotoxic T lymphocyte-associated protein-4(CTLA-4) inhibitors, had made ...
LI Xiangmin, FAN Zaiwen
doaj   +1 more source

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

Frontiers in Cell and Developmental Biology, 2020
Therapies that target oncogenes and immune checkpoint molecules constitute a major group of treatments for metastatic melanoma. A mutation in BRAF (BRAF V600E) affects various signaling pathways, including mitogen activated protein kinase (MAPK) and PI3K/
Minjeong Yeon, Youngmi Kim, Hyun Suk Jung, Dooil Jeoung   +3 more
doaj   +1 more source

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors

Cancer Biology & Medicine, 2015
Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor ...
Jennifer Kleponis, Richard Skelton, Lei Zheng   +2 more
doaj   +1 more source

Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients

Kidney International Reports, 2020
Introduction: Kidney transplant (Ktx) recipients are excluded from clinical trials of immune checkpoint inhibitors. The aim of this systematic review was to assess the safety of immune checkpoint inhibitors among Ktx patients.
Sandhya Manohar, Charat Thongprayoon, Wisit Cheungpasitporn, Svetomir N. Markovic, Sandra M. Herrmann   +4 more
doaj   +1 more source

The gut microbiota and immune checkpoint inhibitors. [PDF]

, 2018
Although immunotherapy has been remarkably effective across multiple cancer types, there continues to be a significant number of non-responding patients. A possible factor proposed to influence the efficacy of immunotherapies is the gut microbiome.
Daud, Adil, Humphries, Audrey
core   +1 more source